20/20 Biolabs receives Nasdaq bid-price deficiency notice, has 180 days to cure
20/20 Biolabs received written notification from Nasdaq on July 17, 2026, that it failed to maintain the $1.00 minimum closing bid price for 30 consecutive business…
Company
SEC filing news and material events for 20/20 Biolabs, Inc., briefed from primary-source filings.
1 story
20/20 Biolabs received written notification from Nasdaq on July 17, 2026, that it failed to maintain the $1.00 minimum closing bid price for 30 consecutive business…